ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.
 PMID: 12176989       2002       The Journal of biological chemistry
Abstract: It was found that, similar to the multidrug-resistant mutant reverse transcriptase (RT)(Q151M), the mutations L74V, M184V, and a triple mutant containing L74V/Y115F/M184V all caused increased selectivity for dGTP over the active metabolite of abacavir (carbovir triphosphate).


  Chemical system biology based molecular interactions to identify inhibitors against Q151M mutant of HIV-1 reverse transcriptase.
 PMID: 12194983       2002       The Journal of biological chemistry
Abstract: The appearance of up to five substitutions (A62V, V75I, F77L, F116Y, and Q151M) in the viral reverse transcriptase promotes resistance to these drugs, and reduces efficiency of the antiretroviral chemotherapy.
Abstract: Using A62V/V75I/F77L/F116Y/Q151M RT, k(pol) increases up to 70- and 13-fold using alpha-boranophosphate-ddATP and alpha-boranophosphate AZTTP, respectively.
Abstract: Using pre-steady state kinetics, we show that Q151M and A62V/


  A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
 PMID: 12212925       2002       Antiviral therapy
Abstract: Compared to WT, MNR HIV-1 RT had 5- to 36-fold increases in the concentration of drug required to inhibit 50% (IC50) of RT activity, depending on the presence of Q151 M alone or with additional MNR mutations.
Abstract: This RT-based phenotypic assay provides a specific and rapid tool for the direct identification and monitoring of Q151M-associated MNR HIV-1 in plasma.
Abstract: This assay exploits the different biochemical mechanisms for zidovudine-resistance conferred by either Q151 M or T215Y/F mutations and the inability of conventional RT assays to detect T215Y/F-associated zidovudine resistance.


  Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1.
 PMID: 12553486       2002       Antiviral therapy
Abstract: Two sets of mutations: the Q151 M complex and the 69 insert, cause resistance to multiple nucleoside analogues.


  Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.
 PMID: 11170234       2001       Journal of clinical laboratory analysis
Abstract: We have found no mutations encoding for multiple dideoxynucleoside resistance (Q151M or T69SS).


  Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
 PMID: 11176267       2001       Journal of acquired immune deficiency syndromes (1999)
Abstract: Multidrug-resistant mutation patterns including Q151M and insertion mutations at codon 69, which confer cross-resistance to the different nucleoside analogue RT inhibitors were detected in 1 and 3 patients, respectively; 1 patient with insertion mutation displayed a NGQGV [corrected] sequence at codons 67 to 70.


  International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
 PMID: 11264998       2001       Journal of acquired immune deficiency syndromes (1999)
Abstract: Other features of NRTI resistance, such as the theoretic reversal of zidovudine resistance associated with the M184V mutation or the powerful influence of the Q151M multiple-drug resistance mutation, have revealed the unpredictable nature of HIV resistance and how much we still need to learn.


  4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
 PMID: 11302824       2001       Antimicrobial agents and chemotherapy
Abstract: These 4'-E analogs also suppressed replication of various drug-resistant HIV-1 clones, including HIV-1(M41L/T215Y), HIV-1(K65R), HIV-1(L74V), HIV-1(M41L/T69S-S-G/T215Y), and HIV-1(A62V/V75I/F77L/F116Y/Q151M).


  Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
 PMID: 11316991       2001       AIDS (London, England)
Abstract: OBJECTIVES: To investigate the genotypic and phenotypic effects of in vitro resistance selection with lamivudine and/or the second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) quinoxaline HBY097 using HIV-1 isolates carrying the multi-nucleoside resistance pattern linked to the Q151M mutation.


  Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients.
 PMID: 11344527       2001       Journal of clinical laboratory analysis
Abstract: Among 432 patients failing antiretroviral therapy, five (1.15%) harboured viruses with Q151M mutation into the RT gene and no viruses were identified harbouring insertion at codon 69.
Abstract: Multiple nucleoside resistance involves specific genetic changes in the HIV-1 reverse transcriptase gene, such as Q151M mutation and an insertion of two serine aminoacids at RT codon 69.



Browser Board

 Co-occurred Entities




   Filtrator